{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=57", "query": { "condition": "Phase I", "page": 57 }, "page_size": 10 }, "pagination": { "page": 57, "page_size": 10, "total_count": 18748, "total_pages": 1875, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=58&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=56&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T08:32:50.687Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04964505", "title": "Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Uproleselan", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brian Jonas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2021-07-02", "completion_date": "2025-10-07", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-11-12T08:32:50.687Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04964505" }, { "nct_id": "NCT00002422", "title": "A Study on the Safety and Anti-HIV Activity of HE2000 in HIV-Infected Patients on Salvage Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "HE2000", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Harbor Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2009-06-25", "last_synced_at": "2026-11-12T08:32:50.687Z", "location_count": 6, "location_summary": "Palm Springs, California • Palo Alto, California • San Francisco, California + 3 more", "locations": [ { "city": "Palm Springs", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002422" }, { "nct_id": "NCT05736731", "title": "A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Solid Tumor", "Pancreatic Cancer", "Pancreatic Neoplasms", "Pancreas Cancer", "Non Small Cell Lung Cancer", "Non Small Cell Lung Cancer Recurrent", "Non-Small Cell Squamous Lung Cancer", "NSCLC", "NSCLC, Recurrent", "Colorectal Cancer", "Colorectal Neoplasms", "Colorectal Adenocarcinoma", "CRC", "Colorectal Cancer Metastatic", "Cancer" ], "interventions": [ { "name": "A2B530", "type": "BIOLOGICAL" }, { "name": "xT-Onco with HLA-LOH Assay", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DIAGNOSTIC_TEST" ], "sponsor": "A2 Biotherapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2023-04-28", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-04-25", "last_synced_at": "2026-11-12T08:32:50.687Z", "location_count": 8, "location_summary": "Gilbert, Arizona • La Jolla, California • Los Angeles, California + 5 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05736731" }, { "nct_id": "NCT04439695", "title": "Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Low dose", "type": "BIOLOGICAL" }, { "name": "Intermediate dose", "type": "BIOLOGICAL" }, { "name": "High dose", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "KBio Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 120, "start_date": "2020-06-25", "completion_date": "2021-07-28", "has_results": false, "last_update_posted_date": "2021-09-16", "last_synced_at": "2026-11-12T08:32:50.687Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04439695" }, { "nct_id": "NCT01120639", "title": "Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma", "Cancer of Brain and Nervous System", "Glioblastoma Multiforme" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" }, { "name": "Stereotactic Radiosurgery (SRS)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2010-04", "completion_date": "2020-11-15", "has_results": true, "last_update_posted_date": "2021-08-06", "last_synced_at": "2026-11-12T08:32:50.687Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01120639" }, { "nct_id": "NCT00605657", "title": "Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "ALPS", "Hypersplenism", "Lymphadenopathy" ], "interventions": [ { "name": "Valproic Acid", "type": "DRUG" }, { "name": "CT Scan", "type": "PROCEDURE" }, { "name": "Blood Sample", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Koneti Rao", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "2 Years to 70 Years" }, "enrollment_count": 6, "start_date": "2008-01", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2013-03-21", "last_synced_at": "2026-11-12T08:32:50.687Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00605657" }, { "nct_id": "NCT00120939", "title": "Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Neoplasms", "Ovarian Neoplasms", "Prostatic Neoplasms", "Lung Neoplasms", "Gastrointestinal Neoplasms" ], "interventions": [ { "name": "Motexafin Gadolinium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacyclics LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2009-04-03", "last_synced_at": "2026-11-12T08:32:50.687Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00120939" }, { "nct_id": "NCT00000773", "title": "Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pneumonia, Pneumocystis Carinii", "HIV Infections" ], "interventions": [ { "name": "Atovaquone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "12 Years", "sex": "ALL", "summary": "1 Month to 12 Years" }, "enrollment_count": 24, "start_date": null, "completion_date": "1996-09", "has_results": false, "last_update_posted_date": "2021-10-28", "last_synced_at": "2026-11-12T08:32:50.687Z", "location_count": 5, "location_summary": "San Francisco, California • Chicago, Illinois • New Orleans, Louisiana + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000773" }, { "nct_id": "NCT01076556", "title": "Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Prolymphocytic Leukemia", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Stage I Chronic Lymphocytic Leukemia", "Stage I Small Lymphocytic Lymphoma", "Stage II Chronic Lymphocytic Leukemia", "Stage II Small Lymphocytic Lymphoma", "Stage III Chronic Lymphocytic Leukemia", "Stage III Small Lymphocytic Lymphoma", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Alvocidib Hydrochloride", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Diagnostic Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2010-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-11-11", "last_synced_at": "2026-11-12T08:32:50.687Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01076556" }, { "nct_id": "NCT00934856", "title": "A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Trastuzumab emtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2009-07", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2017-04-06", "last_synced_at": "2026-11-12T08:32:50.687Z", "location_count": 2, "location_summary": "Charlotte, North Carolina • Houston, Texas", "locations": [ { "city": "Charlotte", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00934856" } ] }